Paul Tudor Jones's ADPT Position Overview
Paul Tudor Jones (via Tudor Investment Corp Et Al) currently holds 543,485 shares of Adaptive Biotechnologies Corporation (ADPT) worth $11.66 M, representing 0.02% of the portfolio. First purchased in 2019-Q2, this medium-term investment has been held for 19 quarters.
Based on 13F filings, Paul Tudor Jones has maintained a strategic position in ADPT, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2024, adding 452,252 shares. Largest reduction occurred in Q2 2026, reducing 242,796 shares.
Analysis based on 13F filings available since 2013 Q2
Paul Tudor Jones's Adaptive Biotechnologies Corporation (ADPT) Holding Value Over Time
Track share changes against reported price movement
Quarterly Adaptive Biotechnologies Corporation (ADPT) Trades by Paul Tudor Jones
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -242,796 | Reduce 30.88% | 543,485 | $21.45 |
| Q1 2026 | +232,244 | Add 41.92% | 786,281 | $13.88 |
| Q4 2025 | -132,356 | Reduce 19.28% | 554,037 | $16.24 |
| Q3 2025 | -174 | Reduce 0.03% | 686,393 | $14.96 |
| Q2 2025 | +172,403 | Add 33.53% | 686,567 | $11.65 |
| Q1 2025 | +55,676 | Add 12.14% | 514,164 | $7.43 |
| Q4 2024 | -57,284 | Reduce 11.11% | 458,488 | $6.00 |
| Q3 2024 | +388 | Add 0.08% | 515,772 | $5.12 |
| Q2 2024 | +452,252 | Add 716.36% | 515,384 | $3.62 |
| Q1 2024 | +63,132 | New Buy | 63,132 | $3.21 |
| Q4 2022 | -134,337 | Sold Out | 0 | $0.00 |
| Q3 2022 | +134,337 | New Buy | 134,337 | $7.12 |
| Q1 2022 | -45,054 | Sold Out | 0 | $0.00 |
| Q4 2021 | +37,732 | Add 515.32% | 45,054 | $28.06 |
| Q3 2021 | -29,221 | Reduce 79.96% | 7,322 | $34.01 |
| Q2 2021 | +29,952 | Add 454.44% | 36,543 | $40.86 |
| Q1 2021 | +6,591 | New Buy | 6,591 | $40.21 |
| Q3 2019 | -5,000 | Sold Out | 0 | $0.00 |
| Q2 2019 | +5,000 | New Buy | 5,000 | $48.40 |
Paul Tudor Jones's Adaptive Biotechnologies Corporation Investment FAQs
Paul Tudor Jones first purchased Adaptive Biotechnologies Corporation (ADPT) in Q2 2019, acquiring 5,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Paul Tudor Jones has held Adaptive Biotechnologies Corporation (ADPT) for 19 quarters since Q2 2019.
Paul Tudor Jones's largest addition to Adaptive Biotechnologies Corporation (ADPT) was in Q2 2024, adding 515,384 shares worth $1.87 M.
According to the latest 13F filing for Q2 2026, Paul Tudor Jones's firm, Tudor Investment Corp Et Al, owns 543,485 shares of Adaptive Biotechnologies Corporation (ADPT), valued at approximately $11.66 M.
As of the Q2 2026 filing, Adaptive Biotechnologies Corporation (ADPT) represents approximately 0.02% of Paul Tudor Jones's publicly disclosed stock portfolio, making it one of their key holdings.
Paul Tudor Jones's peak holding in Adaptive Biotechnologies Corporation (ADPT) was 786,281 shares, as reported at the end of Q1 2026.